A phase III, open label, multicentre randomised clinical study comparing Acelarin (NUC1031) with gemcitabine in patient with metastatic pancreatic carcinoma (ACELARATE)
To evaluate the efficacy and safety of Acelarin compared with gemcitabine in patients with metastatic pancreatic carcinoma. Exploratory objectives are to discover possible biomarkers to predict additional benefit of Acelarin over gemcitabine for subsequent validation.
NRES Committee East Midlands - Nottingham 2, 07/04/2015, ref: 15/EM/0095
Randomised; Interventional; Design type: Treatment
Primary study design
Secondary study design
Randomised controlled trial
Patient information sheet
Not available in web format, please use contact details to request a participant information sheet
Topic: Cancer; Subtopic: Upper Gastro-Intestinal Cancer; Disease: Pancreas
Arm 1: Acelarin: 825 mg/m2 administered intravenously on days 1, 8 and 15 of a 28 day cycle.
Arm 2: Gemcitabine 1000mg/m2 administered intravenously on days 1, 8 and 15 of a 28 day cycle.
Randomisation will be stratified by ECOG performance status (PS) (0/1 vs 2). The planned treatment duration per patient will be until progression of disease, unacceptable toxicity or withdrawal of consent. Participation in the study will be until withdrawal of consent or death. Patients who stop treatment before having developed progressive disease (PD) will be assessed every 12 weeks for response until PD occurs. Patients will receive screening CT scan and ECG. Lung function test at baseline and end of treatment. CT scan every 12 weeks after screening until PD as per RECIST 1.1. Optional additional biopsy for translational biomarker analysis. Optional translational blood sample taken at baseline, day 1 of each cycle and end of treatment.
Primary outcome measures
Overall survival; Timepoint(s): Date of randomisation to date of death.
Secondary outcome measures
1. Discover possible biomarkers to predict additional benefit of Acelarin over gemcitabine alone; Timepoint(s): For subsequent validation in larger scale studies
2. Progression Free Survival; Timepoint(s): Date of randomisation to the earlier of date of progressive disease, date of death or censoring date
3. Quality of life; Timepoint(s): Assessed using the EORTC QLQ-C30 v3 and EORTC QLQ-PAN26 throughout the study and 3 monthly follow up
4. Radiological response and disease control rate; Timepoint(s): Objective radiological response is defined as occurrence of complete (CR) or partial responders (PR)
5. Safety; Timepoint(s): Occurrence of SAE or grade 3+ toxicity measured until 30 days after last study treatment
Overall trial start date
Overall trial end date
Participant inclusion criteria
1. Aged at least 18 years
2. Histologically or cytologically proven pancreatic ductal adenocarcinoma or undifferentiated carcinoma of the pancreas*
3. Metastatic disease precluding curative surgical resection or definitive locally directed therapies such as chemo radiation. Patients who have relapsed following previously resected pancreatic cancer can be included
4. Contrast enhanced computerised tomography (CT) scan of the thorax, abdomen and pelvis within 28 days prior to commencing treatment
5. Unidimensionally measurable disease
6. ECOG performance status 0, 1 or 2 where treatment with combination chemotherapy is not deemed appropriate or is declined by the patient
7. Platelets =100 x 109/l; neutrophils = 1.5 x 109/l at entry
8. Documented life expectancy > 3 months
9. Informed written consent
*Patients will be approached for consenting to provide either an additional core of tissue material for biomarker discovery at the same time as a diagnostic biopsy or in those patients that have already had a diagnostic biopsy to undergo a second biopsy after randomisation into the trial. Neither of these biopsies is compulsory. Patients who don't wish to have extra tissue taken for Biomarker discovery will be approached for consent to released surplus tissue from the original diagnostic specimen if this exists
Target number of participants
Planned Sample Size: 328; UK Sample Size: 328; Description: From our own data for recruitment to advanced pancreatic cancer trials (VIP and Telovac), we can estimate that this would require 328 patients in total yielding 270 deaths - assuming that 4 sites opened/month to a total of 40 sites with mean recruitment rate 0.39 pts/site/month, and 36 month study duration inclusive of 10 month minimum follow-up (excluding time for set-up and closedown).
Participant exclusion criteria
1. Laboratory results:
1.1. Serum bilirubin = 1.5x the upper limit of reference range (ULRR)
1.2. Haemoglobin < 10G/dl
1.3. Creatinine clearance < 30 mL/minute (calculated by CockcroftGault formula)
1.4. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) or alkaline phosphatase (ALP) >2.5 x ULN or > 5x ULN if judged by the investigator to be related to liver metastases.
2. Medical or psychiatric conditions compromising informed consent.
3. Intracerebral metastases or meningeal carcinomatosis.
4. Evidence of severe or uncontrolled systemic disease or any concurrent condition which in the Investigator’s opinion makes it undesirable for the patient to participate in the trial or which would
jeopardize compliance with the protocol.
5. Pregnancy or breast feeding.
6. Previous chemotherapy for locally advanced and metastatic disease. Adjuvant chemotherapy for resected pancreatic cancer will be permitted provided that chemotherapy was completed > 12 months previously.
7. Radiotherapy within the last 4 weeks prior to start of study treatment.
8. Concurrent malignancies or invasive cancers diagnosed within past 5 years except for adequately treated basal cell carcinoma of the skin, in situ carcinoma of the uterine cervix or resected pancreatic cancer.
9. Hypersensitivity to gemcitabine or any of the excipients of gemcitabine or Acelarin (NUC1031).
10. All men or women of reproductive potential, unless using at least two contraceptive precautions, one of which must be from the list below, the other must be a condom (1) or abstaining from sexual intercourse, until six months after treatment has ended:
10.1. Combined (oestrogen and progesterone containing) hormonal contraception associated with inhibition of ovulation: either oral, intravaginal or transdermal.
10.2. Progesterone-only hormonal contraception associated with inhibition of ovulation: either oral, injectable or implantable.
10.3. Intrauterine device (IUD)
10.4. Intrauterine hormonereleasing system (IUS)
10.5. Bilateral tubal occlusion
10.6. Vasectomised partner (2)
10.7. Sexual abstinence (3)
(1) Male or female condom with or without spermicide is not an acceptable method of contraception alone.
(2) Vasectomised partner is a highly effective birth control method provided that partner is the sole sexual partner of the woman of childbearing potential trial participant and that the vasectomised partner has received medical assessment of the surgical success.
(3) In the context of this guidance sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated
with the study treatments. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the subject.
Recruitment start date
Recruitment end date
Countries of recruitment
Trial participating centre
Liverpool Cancer Trials Unit
Cancer Research UK University of Liverpool 1st floor Block C, Waterhouse Building 3 Brownlow Street
NuCana BioMed LTD
Funding Body Type
Funding Body Subtype
Results and Publications
Publication and dissemination plan
We intend to publish the study results with regard to the primary and secondary endpoints upon completion of the study. The abstract will be discussed at meetings and will be in peer reviewed papers.
Intention to publish date
Participant level data
Available on request
Results - basic reporting